Putting the immune system in control
DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after standard of care therapy to delay or prevent disease recurrence. Relapse vaccines are aimed at improving survival by putting the patient’s immune system back in control while tumor burden is low, and the immune system is in relatively good shape.
A growing pipeline of relapse vaccines
Our lead product DCP-001 is a cell-based vaccine addressing blood cancers with a high risk of relapse. DCP-001 is currently being evaluated in a Phase II clinical trial in acute myeloid leukemia (AML). We are pursuing similar vaccination approaches in other malignancies, including solid tumors.